TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Meditation Intervention for the Treatment of Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Randomized Control Trial
Brief Summary: This study examines the use of brief meditation interventions for patients with symptoms of anxiety and depression who are undergoing dialysis. Half of the participants will receive meditation interventions 3 times a week, while the other half will receive treatment as usual. This study will examine whether meditation is feasible and whether it has any effect on reducing symptoms of anxiety or depression.


Options:
A: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: Meditation Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: Meditation | Arm Label: Control Group (No Meditation Exposure); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Meditation; Assigned to Arm(s): Meditation Intervention Arm
C: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage: A Randomized Controlled Trial.
Brief Summary: The aim of this work is to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of first trimester missed miscarriage.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2
C: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin
D: Arm Label: sublingual misoprostol; Type: EXPERIMENTAL; Interventions: Drug: sublingual misoprostol | Arm Label: vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Intervention Type: DRUG; Name: sublingual misoprostol; Assigned to Arm(s): sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): vaginal misoprostol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage: A Randomized Controlled Trial.
Brief Summary: The aim of this work is to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of first trimester missed miscarriage.


Options:
A: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
B: Arm Label: mifepristone+misoprostol; Type: EXPERIMENTAL; Interventions: Drug: mifepristone, Drug: misoprostol | Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol, Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone+misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): mifepristone+misoprostol, misoprostol | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): misoprostol
C: Arm Label: Midlevel provider; Type: OTHER; Interventions: Other: Type of provider | Arm Label: Physician arm; Type: OTHER; Interventions: Other: Type of provider | Intervention Type: OTHER; Name: Type of provider; Assigned to Arm(s): Midlevel provider, Physician arm
D: Arm Label: sublingual misoprostol; Type: EXPERIMENTAL; Interventions: Drug: sublingual misoprostol | Arm Label: vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Intervention Type: DRUG; Name: sublingual misoprostol; Assigned to Arm(s): sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): vaginal misoprostol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty
Brief Summary: The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the total blood loss associated with the total knee arthroplasty.


Options:
A: Arm Label: TT-173; Type: EXPERIMENTAL; Interventions: Biological: TT-173 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: TT-173; Assigned to Arm(s): TT-173
B: Arm Label: Evicel; Type: EXPERIMENTAL; Interventions: Drug: Evicel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Evicel; Assigned to Arm(s): Evicel
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Comparator
D: Arm Label: Peri-articular group; Type: EXPERIMENTAL; Interventions: Drug: Peri-articular tranexamic acid | Arm Label: Intravenous group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous tranexamic acid | Intervention Type: DRUG; Name: Peri-articular tranexamic acid; Assigned to Arm(s): Peri-articular group | Intervention Type: DRUG; Name: Intravenous tranexamic acid; Assigned to Arm(s): Intravenous group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Copeptin: Predictive Value and Risk Stratification in Patients Undergoing Major Surgery
Brief Summary: Observational cohort study examining the perioperative course of copeptin in patients undergoing elevated-risk surgery.


Options:
A: N/A
B: N/A
C: N/A
D: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D to Prevent Severe Asthma Exacerbations
Brief Summary: This study will determine whether vitamin D3 prevents severe asthma attacks in children who have a serum vitamin D (25(OH)D) level \<30 ng/ml and who are being treated with inhaled corticosteroids for asthma. Half the participants will receive vitamin D3 at a dose of 4,000 IU/day, and the other half will receive placebo.


Options:
A: Arm Label: vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: vitamin D3 4000 IU | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: vitamin D3 4000 IU; Assigned to Arm(s): vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vitamin D3 + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: fish oil | Arm Label: Vitamin D3 + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D3 placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: fish oil, Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D3 placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D3 placebo + fish oil, Vitamin D3 placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D3 + fish oil placebo, Vitamin D3 placebo + fish oil placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial on Central Venous Catheterization Techniques in Neonates: Seldinger Versus Modified Seldinger
Brief Summary: The purpose of this study is to compare the differences in central venous catheter insertion time, success rate, and complication between the Seldinger and modified Seldinger technique for ultrasound-guided central venous catheterization in neonates.


Options:
A: Arm Label: Palpation only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RAP palpation only | Arm Label: Ultrasound guidance; Type: EXPERIMENTAL; Interventions: Procedure: RAP with ultrasound guidance | Intervention Type: PROCEDURE; Name: RAP palpation only; Assigned to Arm(s): Palpation only | Intervention Type: PROCEDURE; Name: RAP with ultrasound guidance; Assigned to Arm(s): Ultrasound guidance
B: Arm Label: Seldinger; Type: EXPERIMENTAL; Interventions: Device: Ultrasound, Other: General anesthesia | Arm Label: Modified Seldinger; Type: EXPERIMENTAL; Interventions: Device: Ultrasound, Other: General anesthesia | Intervention Type: DEVICE; Name: Ultrasound; Assigned to Arm(s): Modified Seldinger, Seldinger | Intervention Type: OTHER; Name: General anesthesia; Assigned to Arm(s): Modified Seldinger, Seldinger
C: Arm Label: Dynamic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dynamic | Arm Label: Regular-triangle; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Regular-triangle | Intervention Type: BEHAVIORAL; Name: dynamic; Assigned to Arm(s): Dynamic | Intervention Type: BEHAVIORAL; Name: Regular-triangle; Assigned to Arm(s): Regular-triangle
D: Arm Label: direct palpation; Type: ACTIVE_COMPARATOR; Interventions: Device: Direct Palpation-guided Radial Artery Catheter insertion | Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound-guided Radial Artery Catheter Insertion | Intervention Type: DEVICE; Name: Ultrasound-guided Radial Artery Catheter Insertion; Assigned to Arm(s): Ultrasound | Intervention Type: DEVICE; Name: Direct Palpation-guided Radial Artery Catheter insertion; Assigned to Arm(s): direct palpation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial
Brief Summary: Background: Effectiveness of Percutaneous transluminal angioplasty and stenting (PTAS) on prevention of events of stroke and death in patients with symptomatic intracranial atherosclerosis (ICAS) is controversial.

Aim: to determine whether PTAS plus medical treatment (MT) are superior to MT alone in preventing events of stroke and death in patients with symptomatic ICAS.

Methods: The investigators will carry out a randomized controlled trial in 3 hospitals in China. A total of 198 patients with ICAS will be randomized into 2 groups: PTAS+MT and MT group. All patients will receive aspirin (100 mg daily) and clopidogrel (75 mg daily) immediately after randomization, and patients in PTAS+MT group will receive surgery within 5 days after randomization. The patients will be followed up for 1 year after randomization and assessed for events of stroke and death at 30 days and 1 year after randomization, the incidence of recurrent ischaemic stroke in the stenting-involved vascular territory at 30 days and 1 year after randomization, incidence of in-stent restenosis at 1 year after randomization,etc.


Options:
A: Arm Label: stenting+medical treatment; Type: EXPERIMENTAL; Interventions: Procedure: Percutaneous transluminal angioplasty and stenting, Drug: Aspirin plus clopidogrel | Arm Label: Aspirin plus clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin plus clopidogrel | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty and stenting; Assigned to Arm(s): stenting+medical treatment | Intervention Type: DRUG; Name: Aspirin plus clopidogrel; Assigned to Arm(s): Aspirin plus clopidogrel, stenting+medical treatment
B: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment
C: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
D: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maxigesic IV Bunionectomy Study- A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group and Placebo-Controlled Study
Brief Summary: The purpose of the study is to determine the clinical efficacy and safety of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV for the treatment of acute postoperative pain after bunionectomy


Options:
A: Arm Label: intravenous ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous ibuprofen | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline as placebo comparator | Intervention Type: OTHER; Name: Normal saline as placebo comparator; Assigned to Arm(s): normal saline | Intervention Type: DRUG; Name: Intravenous ibuprofen; Assigned to Arm(s): intravenous ibuprofen
B: Arm Label: ibuprofen( 400mg group); Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: ibuprofen( 800mg group); Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen( 400mg group), ibuprofen( 800mg group) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group
C: Arm Label: Maxigesic IV; Type: EXPERIMENTAL; Interventions: Drug: Maxigesic IV | Arm Label: IV Acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Acetaminophen | Arm Label: IV Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ibuprofen | Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV | Intervention Type: DRUG; Name: Maxigesic IV; Assigned to Arm(s): Maxigesic IV | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen | Intervention Type: DRUG; Name: IV Ibuprofen; Assigned to Arm(s): IV Ibuprofen | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Placebo IV
D: Arm Label: IV Caldolor (ibuprofen); Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Caldolor | Arm Label: standard treatment group; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Intervention Type: DRUG; Name: IV Caldolor; Assigned to Arm(s): IV Caldolor (ibuprofen) | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): standard treatment group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients
Brief Summary: A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients.


Options:
A: Arm Label: IBR + OB; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Obinutuzumab | Arm Label: CLB + OB; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): IBR + OB | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): CLB + OB, IBR + OB | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): CLB + OB
B: Arm Label: Arm A (PCO, closed to accrual as of 8/23/2011); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Arm Label: Arm B (PCO with ofatumumab consolidation); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: BIOLOGICAL; Name: Ofatumumab; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation)
C: Arm Label: Bendamustine + GA101 + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib
D: Arm Label: Bendamustine + Ofatumumab + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Ofatumumab, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed: An Open Label Randomized Controlled Trial.
Brief Summary: All patients with non variceal bleed who are admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who meet the inclusion criteria and who provide informed consent.


Options:
A: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive
B: Arm Label: Thromboelastography (TEG) level; Type: EXPERIMENTAL; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Arm Label: Coagulation Profile; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Intervention Type: BIOLOGICAL; Name: Fresh Frozen Plasma; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Platelets Concentrate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Cryo Precitipitate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level
C: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
D: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion

Answer: B